Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA4 | P22748 | 6/20 | 0.43 |
| ▸ | CA7 | P43166 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | WDR5 | P61964 | 5/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375673 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4373586 | 0.88 | BTK (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4374705 | 0.88 | BTK (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4378379 | 0.88 | CA12 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4380239 | 0.86 | CA12 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4373803 | 0.86 | L3MBTL1 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4370332 | 0.85 | L3MBTL1 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4378349 | 0.84 | FLT1 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4375671 | 0.84 | FLT1 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4373275 | 0.84 | CA12 (0.44) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101300231-B | Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | claimed |
| CN-101300231-A | Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | CN | claimed |
| EP-1960361-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | claimed |
| WO-2007059872-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F. HOFFMNN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | claimed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | claimed |
| CN-101300231-B | Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | disclosed |
| US-7625896-B2 | Pyridylsulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090057800-A1 | SMALL-SIZE MODULE | KABUSHIKI KAISHA TOSHIBA (JP) | 2009-03-05 | — | — | US | disclosed |
| CN-101300231-A | Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | CN | disclosed |
| EP-1960361-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007059872-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F. HOFFMNN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | TPMT, BPNT1, SLC6A3 | CA12 1030/4885CA1 1442/4885CA2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.